← Back to Treatments
🏅 FDA Orphan Designation

LORBRENA

Lorlatinib

Manufacturer: Pfizer, Inc.

Indicated for:
NON RARE IN EUROPE: Non-small cell lung cancerOrphan

FDA-Approved Indications (1)

LORBRENA� is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at le…

Indications & Usage

1 INDICATIONS AND USAGE LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ( 1 , 2.1 )

💙 Support Programs

View all →
Lorbrena
Pfizer
Copay card ↗Apply ↗
LORBRENA
Pfizer, Inc.
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.